Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-Positive Breast Cancer Following Endocrine Therapy.

Peiffer DS, Wyatt D, Zlobin A, Piracha A, Ng J, Dingwall AK, Albain KS, Osipo C.

Cancer Res. 2019 Oct 1;79(19):4965-4977. doi: 10.1158/0008-5472.CAN-19-1110. Epub 2019 Aug 6.

PMID:
31387918
2.

Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1.

Shah D, Wyatt D, Baker AT, Simms P, Peiffer DS, Fernandez M, Rakha E, Green A, Filipovic A, Miele L, Osipo C.

Clin Cancer Res. 2018 Sep 15;24(18):4566-4578. doi: 10.1158/1078-0432.CCR-17-1952. Epub 2018 Jun 12.

3.

Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.

Baker A, Wyatt D, Bocchetta M, Li J, Filipovic A, Green A, Peiffer DS, Fuqua S, Miele L, Albain KS, Osipo C.

Oncogene. 2018 Aug;37(33):4489-4504. doi: 10.1038/s41388-018-0251-y. Epub 2018 May 10.

PMID:
29743588
4.

Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer.

Fukushiro-Lopes DF, Hegel AD, Rao V, Wyatt D, Baker A, Breuer EK, Osipo C, Zartman JJ, Burnette M, Kaja S, Kouzoukas D, Burris S, Jones WK, Gentile S.

Oncotarget. 2017 Dec 4;9(3):3321-3337. doi: 10.18632/oncotarget.22925. eCollection 2018 Jan 9.

5.

Deubiquitinase OTUD6B Isoforms Are Important Regulators of Growth and Proliferation.

Sobol A, Askonas C, Alani S, Weber MJ, Ananthanarayanan V, Osipo C, Bocchetta M.

Mol Cancer Res. 2017 Feb;15(2):117-127. doi: 10.1158/1541-7786.MCR-16-0281-T. Epub 2016 Nov 18.

6.

Cancer stem cells and HER2 positive breast cancer: The story so far.

Shah D, Osipo C.

Genes Dis. 2016 Jun;3(2):114-123. doi: 10.1016/j.gendis.2016.02.002. Epub 2016 Feb 21.

7.

ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation.

Nunes J, Zhang H, Angelopoulos N, Chhetri J, Osipo C, Grothey A, Stebbing J, Giamas G.

Oncotarget. 2016 May 10;7(19):27599-612. doi: 10.18632/oncotarget.8504.

8.

The role of Rak in the regulation of stability and function of BRCA1.

Kim JL, Ha GH, Campo L, Denning MF, Patel TB, Osipo C, Lin SY, Breuer EK.

Oncotarget. 2015 Oct 14;8(49):86799-86815. doi: 10.18632/oncotarget.5717. eCollection 2017 Oct 17.

9.

PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.

Pandya K, Wyatt D, Gallagher B, Shah D, Baker A, Bloodworth J, Zlobin A, Pannuti A, Green A, Ellis IO, Filipovic A, Sagert J, Rana A, Albain KS, Miele L, Denning MF, Osipo C.

Clin Cancer Res. 2016 Jan 1;22(1):175-86. doi: 10.1158/1078-0432.CCR-15-0179. Epub 2015 Sep 8.

10.

Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.

Das S, Sondarva G, Viswakarma N, Nair RS, Osipo C, Tzivion G, Rana B, Rana A.

J Biol Chem. 2015 Aug 28;290(35):21705-12. doi: 10.1074/jbc.M115.655563. Epub 2015 Jul 7.

11.

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer.

Baker AT, Zlobin A, Osipo C.

Front Oncol. 2014 Dec 12;4:360. doi: 10.3389/fonc.2014.00360. eCollection 2014. Review.

12.

Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer.

Weber CE, Kothari AN, Wai PY, Li NY, Driver J, Zapf MA, Franzen CA, Gupta GN, Osipo C, Zlobin A, Syn WK, Zhang J, Kuo PC, Mi Z.

Oncogene. 2015 Sep 10;34(37):4821-33. doi: 10.1038/onc.2014.410. Epub 2014 Dec 22.

13.

Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells.

Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, Caskey M, Rizzo P, D'Souza G, Backus K, Denning MF, Coon J, Sun M, Bresnick EH, Osipo C, Wu J, Strack PR, Tonetti DA, Miele L.

Oncogenesis. 2013 Aug 5;2:e60. doi: 10.1038/oncsis.2013.26.

14.

Gamma secretase inhibitors of Notch signaling.

Olsauskas-Kuprys R, Zlobin A, Osipo C.

Onco Targets Ther. 2013 Jul 23;6:943-55. doi: 10.2147/OTT.S33766. Print 2013.

15.

The functional role of Notch signaling in triple-negative breast cancer.

Speiser JJ, Erşahin C, Osipo C.

Vitam Horm. 2013;93:277-306. doi: 10.1016/B978-0-12-416673-8.00013-7. Review.

PMID:
23810012
16.

Evaluation of biomarkers in multifocal/multicentric invasive breast carcinomas.

Pekmezci M, Szpaderska A, Osipo C, Erşahin Ç.

Int J Surg Pathol. 2013 Apr;21(2):126-32. doi: 10.1177/1066896912467370. Epub 2012 Nov 30.

PMID:
23204031
17.

The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma.

Pekmezci M, Szpaderska A, Osipo C, Erşahin C.

Patholog Res Int. 2012;2012:947041. doi: 10.1155/2012/947041. Epub 2012 Mar 11.

18.

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.

Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS, Osipo C.

Br J Cancer. 2011 Sep 6;105(6):796-806. doi: 10.1038/bjc.2011.321. Epub 2011 Aug 16.

19.

NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.

Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C.

Breast Cancer Res. 2011 Jun 14;13(3):R63. doi: 10.1186/bcr2900.

20.

Targeting Notch to target cancer stem cells.

Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L.

Clin Cancer Res. 2010 Jun 15;16(12):3141-52. doi: 10.1158/1078-0432.CCR-09-2823. Epub 2010 Jun 8. Review.

21.

Trastuzumab resistance: role for Notch signaling.

Mehta K, Osipo C.

ScientificWorldJournal. 2009 Dec 16;9:1438-48. doi: 10.1100/tsw.2009.166. Review.

22.

Notch versus the proteasome: what is the target of gamma-secretase inhibitor-I?

Clementz AG, Osipo C.

Breast Cancer Res. 2009;11(5):110. doi: 10.1186/bcr2407.

23.

Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.

Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW, Sonenshein G, Osborne BA, Miele L.

Oncogene. 2010 Jan 14;29(2):201-13. doi: 10.1038/onc.2009.323. Epub 2009 Oct 19.

24.

Targeting Notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer.

Rizzo P, Osipo C, Pannuti A, Golde T, Osborne B, Miele L.

Adv Enzyme Regul. 2009;49(1):134-41. doi: 10.1016/j.advenzreg.2009.01.008. Epub 2009 Jan 20. Review. No abstract available.

PMID:
19344631
25.

Rational targeting of Notch signaling in cancer.

Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L.

Oncogene. 2008 Sep 1;27(38):5124-31. doi: 10.1038/onc.2008.226. Review.

PMID:
18758481
26.

Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches.

Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ, Miele L.

Cancer Res. 2008 Jul 1;68(13):5226-35. doi: 10.1158/0008-5472.CAN-07-5744. Erratum in: Cancer Res. 2008 Sep 1;68(17):7246. Song, Lynda L [added].

27.

ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.

Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L.

Oncogene. 2008 Aug 28;27(37):5019-32. doi: 10.1038/onc.2008.149. Epub 2008 May 12.

PMID:
18469855
28.

Off the beaten pathway: the complex cross talk between Notch and NF-kappaB.

Osipo C, Golde TE, Osborne BA, Miele LA.

Lab Invest. 2008 Jan;88(1):11-7. Epub 2007 Dec 3.

29.

Intracellular distribution of TiO2-DNA oligonucleotide nanoconjugates directed to nucleolus and mitochondria indicates sequence specificity.

Paunesku T, Vogt S, Lai B, Maser J, Stojićević N, Thurn KT, Osipo C, Liu H, Legnini D, Wang Z, Lee C, Woloschak GE.

Nano Lett. 2007 Mar;7(3):596-601. Epub 2007 Feb 3.

30.

Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.

Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC.

Int J Oncol. 2007 Feb;30(2):509-20.

PMID:
17203234
31.

Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.

Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC.

Int J Oncol. 2006 Nov;29(5):1237-46.

PMID:
17016657
32.

Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.

O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2255-63.

33.

Hedgehog signaling in hepatocellular carcinoma: novel therapeutic strategy targeting hedgehog signaling in HCC.

Osipo C, Miele L.

Cancer Biol Ther. 2006 Feb;5(2):238-9. Epub 2006 Feb 7. No abstract available.

PMID:
16552173
34.

Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.

Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC.

J Natl Cancer Inst. 2005 Dec 7;97(23):1746-59.

PMID:
16333030
35.

MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis.

Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL Jr, Gartenhaus RB.

Cancer Res. 2005 Dec 1;65(23):10651-6.

36.

The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy.

Jordan VC, Lewis JS, Osipo C, Cheng D.

Breast. 2005 Dec;14(6):624-30. Epub 2005 Oct 3. Review.

PMID:
16202599
37.

Trastuzumab therapy for tamoxifen-stimulated endometrial cancer.

Osipo C, Meeke K, Liu H, Cheng D, Lim S, Weichel A, Jordan VC.

Cancer Res. 2005 Sep 15;65(18):8504-13.

38.

Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal.

Lewis JS, Osipo C, Meeke K, Jordan VC.

J Steroid Biochem Mol Biol. 2005 Feb;94(1-3):131-41. Epub 2005 Feb 8.

PMID:
15862958
39.

Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.

Osipo C, Gajdos C, Cheng D, Jordan VC.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):249-56.

PMID:
15860267
40.

The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death.

Osipo C, Liu H, Meeke K, Jordan VC.

Exp Biol Med (Maywood). 2004 Sep;229(8):722-31. Review.

PMID:
15337826
41.

Changing role of the oestrogen receptor in the life and death of breast cancer cells.

Jordan VC, Osipo C, Schafer JM, Fox JE, Cheng D, Liu H.

Breast. 2003 Dec;12(6):432-41. Review.

PMID:
14659118
42.

Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.

Osipo C, Gajdos C, Liu H, Chen B, Jordan VC.

J Natl Cancer Inst. 2003 Nov 5;95(21):1597-608.

PMID:
14600092
43.

Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.

Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan VC.

J Natl Cancer Inst. 2003 Nov 5;95(21):1586-97.

PMID:
14600091
44.

Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.

Dardes RC, Schafer JM, Pearce ST, Osipo C, Chen B, Jordan VC.

Gynecol Oncol. 2002 Jun;85(3):498-506.

PMID:
12051881

Supplemental Content

Support Center